Recent investigations highlight TIM-3’s significance in the context of T cell exhaustion and its correlation with the efficacy of anti-PD-1 therapy, suggesting that targeting TIM-3 could represent a promising strategy in the realm of cancer immunotherapy (4). Here, HAVCR2 is linked to cancer.